Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMinneapolis Heart Institute Foundation
About this trial
The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.
Eligibility criteria
Qualifiers
Patients with their first STEMI (>18 years) who underwent successful primary PCI and able to give informed consent
At least mild LV dysfunction (LVEF < 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI
Infarct size that is > 10% of LV mass
The presence of MVO that is > 10% of infarct size
Disqualifiers
Contraindication to cardiac MRI
Life expectancy < 1 year
Previous CABG or Valve Surgery
Previous STEMI
Trial design
Treatments tested in this trial
- SGLT-2 inhibitors
- Placebo
Treatment groups
81 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov